Amuvatinib is primarily investigated for its potential in cancer therapy, particularly in targeting certain types of tumors. It works by inhibiting specific tyrosine kinases, which are enzymes that play a crucial role in the growth and spread of cancer cells. This inhibition can help in slowing down or stopping the progression of cancer. One of the key applications of Amuvatinib is in the treatment of small cell lung cancer (SCLC) and gastrointestinal stromal tumors (GIST). It has shown promise in preclinical studies by enhancing the effectiveness of other chemotherapy agents, making it a candidate for combination therapy. Additionally, Amuvatinib has been studied for its role in overcoming resistance to certain cancer treatments, thereby improving patient outcomes. Research is ongoing to explore its efficacy in other types of cancers and to better understand its mechanism of action, with the aim of developing more targeted and effective cancer therapies.